All HER2-negative breast cancer patients need gBRCA testing: cost-effectiveness and clinical benefits

BACKGROUND: The OlympiA trial demonstrated the benefits of adjuvant usage of olaparib for high-risk patients with human epidermal growth factor receptor 2 (HER2)-negative breast cancer (BC) and germline BRCA (gBRCA) mutation. This provoked thoughts on the clinical criteria of gBRCA testing. This stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Huai-liang, Luo, Zi-yin, He, Zong-lin, Gong, Yue, Mo, Miao, Ming, Wai-kit, Liu, Guang-yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9938252/
https://www.ncbi.nlm.nih.gov/pubmed/36564566
http://dx.doi.org/10.1038/s41416-022-02111-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9938252/
https://www.ncbi.nlm.nih.gov/pubmed/36564566
http://dx.doi.org/10.1038/s41416-022-02111-y

Ejemplares similares